OTCMKTS:NVZMY - Novozymes A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $425.00
  • Forecasted Upside: 603.53 %
  • Number of Analysts: 8
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$60.41
▲ +0.38 (0.63%)

This chart shows the closing price for NVZMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novozymes A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVZMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVZMY

Analyst Price Target is $425.00
▲ +603.53% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Novozymes A/S in the last 3 months. The average price target is $425.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 603.53% upside from the last price of $60.41.

This chart shows the closing price for NVZMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 investment analysts is to hold stock in Novozymes A/S. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 3 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/29/2022Kepler Capital MarketsUpgradeReduce ➝ Hold
4/27/2022Nordea Equity ResearchUpgradeSell ➝ Hold
3/30/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
3/17/2022BarclaysLower Price Target510.00 ➝ 490.00
2/4/2022Credit Suisse GroupLower Price TargetUnderperform ➝ Underperform390.00 ➝ 360.00
10/29/2021CitigroupReiterated RatingNeutral
10/28/2021UBS GroupReiterated RatingSell
9/2/2021BarclaysReiterated RatingOverweight
8/23/2021Berenberg BankUpgradeHold ➝ Buy
8/16/2021Credit Suisse GroupReiterated RatingUnderperform
8/13/2021UBS GroupReiterated RatingSell
7/28/2021BarclaysReiterated RatingOverweight
7/14/2021UBS GroupReiterated RatingSell
5/10/2021BarclaysReiterated RatingOverweight
5/4/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
4/30/2021Berenberg BankReiterated RatingHold
4/28/2021UBS GroupReiterated RatingSell
4/28/2021Credit Suisse GroupReiterated RatingUnderperform
4/28/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
2/9/2021BarclaysReiterated RatingOverweight
2/3/2021Berenberg BankUpgradeSell ➝ Hold
1/26/2021DanskeUpgradeSell ➝ Hold
1/25/2021BarclaysUpgradeUnderweight ➝ Overweight
11/18/2020BarclaysReiterated RatingUnderweight
10/8/2020Berenberg BankDowngradeHold ➝ Sell
10/1/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
8/13/2020BarclaysReiterated RatingUnderweight
7/28/2020BarclaysInitiated CoverageUnderweight
7/8/2020UBS GroupReiterated RatingSell
7/2/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
5/12/2020Credit Suisse GroupDowngradeOutperform ➝ Underperform
4/1/2020The Goldman Sachs GroupDowngradeBuy ➝ Sell
1/14/2020BNP ParibasDowngradeOutperform ➝ Neutral
1/7/2020The Goldman Sachs GroupInitiated CoverageBuy
12/17/2019Berenberg BankDowngradeBuy ➝ Hold
11/20/2019CitigroupUpgradeNeutral ➝ Buy
9/30/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
8/19/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
3/26/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
2/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy
2/5/2019Berenberg BankUpgradeHold ➝ Buy
1/30/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
1/28/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral
12/20/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
10/30/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
3/5/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
10/26/2017Jefferies Financial GroupReiterated RatingHold$54.97
8/14/2017Jefferies Financial GroupSet Price TargetHold$48.00
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Novozymes A/S logo
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Read More

Today's Range

Now: $60.41
Low: $59.48
High: $60.63

50 Day Range

MA: $61.84
Low: $55.87
High: $70.04

52 Week Range

Now: $60.41
Low: $55.02
High: $83.31

Volume

12,100 shs

Average Volume

19,682 shs

Market Capitalization

$13.73 billion

P/E Ratio

33.38

Dividend Yield

0.91%

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Novozymes A/S?

The following Wall Street research analysts have issued research reports on Novozymes A/S in the last year: Barclays PLC, Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Kepler Capital Markets, Nordea Equity Research, and UBS Group AG.
View the latest analyst ratings for NVZMY.

What is the current price target for Novozymes A/S?

0 Wall Street analysts have set twelve-month price targets for Novozymes A/S in the last year. Their average twelve-month price target is $425.00, suggesting a possible upside of 603.5%.
View the latest price targets for NVZMY.

What is the current consensus analyst rating for Novozymes A/S?

Novozymes A/S currently has 2 sell ratings, 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVZMY, but not buy more shares or sell existing shares.
View the latest ratings for NVZMY.

How do I contact Novozymes A/S's investor relations team?

Novozymes A/S's physical mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company's listed phone number is (454) 446-0000 and its investor relations email address is [email protected] The official website for Novozymes A/S is www.novozymes.com. Learn More about contacing Novozymes A/S investor relations.